Artiva Biotherapeutics

Artiva Biotherapeutics is a biotechnology company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer treatment. They leverage proprietary manufacturing processes to produce NK cells at scale, aiming to provide effective and accessible immunotherapies. Founded in 2019, Artiva has established strategic partnerships, including collaborations with Merck and other leading pharmaceutical companies, to advance their clinical programs and expand their therapeutic pipeline. Their innovative approach aims to address the limitations of current cell therapies, offering promising solutions for patients with various types of cancer.

Recent Posts by Artiva Biotherapeutics

1-20 of 25